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Mitochondrial respiratory chain (RC) disorders are a group of genetically and clinically heterogeneous diseases. This is because
protein components of the RC are encoded by bothmitochondrial and nuclear genomes and are essential in all cells. In addition, the
biogenesis and maintenance of mitochondria, including mitochondrial DNA (mtDNA) replication, transcription, and translation,
require nuclear-encoded genes. In the past decade, a growing number of syndromes associated with dysfunction of mtDNA
translation have been reported. This paper reviews the current knowledge of mutations affecting mitochondrial aminoacyl tRNAs
synthetases and their role in the pathogenic mechanisms underlying the different clinical presentations.
1. Introduction
Mitochondria are double-membrane cytoplasmic organelles
essential for energy supply to the cell. Adenosine-5󸀠-
triphosphate (ATP), the molecular unit of currency for
intracellular energy transfer, is produced by the last of five
multisubunit complexes embedded in the inner mitochon-
drial membrane, which form the respiratory chain (RC)
responsible for oxidative phosphorylation (OXPHOS).
Mitochondria have their own DNA (mtDNA) that is a
circular, double-stranded molecule; in humans, it is 16.569
base pairs long and contains genes encoding 13 protein
subunits of RC complexes I, III, IV, andVaswell as transfer (t)
and ribosomal (r) RNA encoding genes for mtDNA-specific
translation. However, hundreds of additional gene products,
providing the components necessary for mtDNA replication
and expression, many RC complex subunits, and the complex
protein network needed for RC formation, activity, and
turnover, are nuclear-encoded.
The term mitochondrial disorder refers to diseases that
are caused by OXPHOS dysfunction and comprises a clini-
cally and genetically heterogeneous group of syndromes that
all together are amongst the most common inherited human
diseases, with a prevalence of 1 : 5000.
Deficiencies of single RC complex are generally caused by
mutations in genes encoding structural subunits or proteins
involved in the assembly of a specific OXPHOS enzyme com-
plex. On the contrary, combined OXPHOS defects are often
associated with impairment of processes such as replication,
transcription, or translation of mtDNA, which can be due
to mutations in either mtDNA-encoded RNAs (tRNAs and
rRNAs) or nuclear DNA-encoded proteins [1, 2]. Hundreds
of RNA and protein factors have been maintained through
evolution of eukaryotes to carry out the synthesis of a few,
but essential, mtDNA-encoded proteins, carried out in situ
by organelle-specific translation machinery [3].
Given the multitude of proteins required for proper
mitochondrial protein synthesis, it is not surprising that
mitochondrial disorders due to impairment of this essential
process are genetically heterogeneous and that, in many
patients, the molecular genetic defect remains unknown.
This review will focus on a group of enzymes with a key
role in mitochondrial protein synthesis, the aminoacyl tRNA
synthetases (mt-aaRSs), mutations of which are responsible
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for an increasing number of OXPHOS deficiencies and
diseases (Table 1).
2. Mitochondrial Protein Synthesis
Protein synthesis is a complex process that in mitochondria
supplies the mtDNA-encoded subunits of RC complexes
through an organellar-specific translational apparatus dis-
tinct from the cytosolic counterpart. In fact, there are some
distinguishing features for the mitochondrial translation,
including the mitochondrial genetic code, which differs from
the universal one (i.e., AUA codes for methionine and UGA,
instead of being a stop codon, codes for tryptophan), and the
structure of mitochondrial mRNAs, which have no or few 5󸀠
untranslated nucleotides, is uncapped and contains a poly (A)
immediately after the stop codon.
The human mitoribosome is made up of 2 ribosomal
RNAs (rRNA) and 81 mitochondrial ribosomal proteins
(MRPs) and comprises two subunits, the small (SSU or 28S)
and the large (LSU or 39S) [3]. Mammalian mitoribosome
differs markedly from bacteria, cytosolic, and also from other
mitochondrial ribosomes, due to the peculiar recruitment
of numerous extraproteins. Most of the protein components
involved in mitochondrial translation such as a multitude
of initiation, elongation and termination factors, subunits
and assembly protein of mitoribosome, tRNA-modifying
enzymes, and the mt-aaRSs are encoded by nuclear genes,
whereas 2 mitochondrial ribosomal and 22 transfer RNAs
(rRNAs and tRNAs) are encoded by mtDNA [4]. Mito-
chondrial mRNA translation has been hypothesized to take
place in a complex bound to the inner membrane through
electrostatic force and maybe protein interaction [5]. The
basic model of mitochondrial protein synthesis is derived
from studies in bacteria and can be divided into three phases:
initiation, elongation, and termination [3, 6].
Due to the unusual characteristics of mitochondrial
mRNA, it is not fully clear how the protein synthesis starts.
It is thought that mitochondrial initiation factor mtIF3 (the
ortholog of prokaryotic IF3) induces the dissociation of the
mitoribosome into its two components, the small (SSU or
28S) and the large (LSU or 39S) subunits. This facilitates
the binding of the mRNA to the SSU subunit directing the
ribosome to the start codon. Mammalian mitochondria use a
single tRNAMet for both the initiation and elongation phases;
after aminoacylation, the tRNAMet needs to be formylated by
methionyl-tRNA transformylase (forming fMet-tRNAMet) to
initiate mitochondrial translation. A second mitochondrial
initiation factor, mtIF2, is required for binding of the fMet-
tRNAMet to the SSU. Recombining of the mitoribosome
subunits and GTP hydrolysis promote the release of mtIF3
and mtIF2 and the completion of the initiation phase.
In the elongation phase, a crucial role is played by the
elongations factors mtEFTu, mtEFTs, and mtEFG (1 and 2).
mtEFTu forms a complex with GTP and a tRNA charged
with its corresponding amino acid, protecting the latter from
hydrolysis and facilitating the codon-anticodon recognition
at the acceptor site A of the SSU. This step requires GTP
hydrolysis and leads to the release ofmtEFTu.The aminoacyl-
tRNA moves into the peptidyl (P) site of the mitoribosome,
where the amino acid is added to the growing peptide.
mtETFs recycles the released mtEFTu-GDP, reforming an
active mtEFTu-GTP. mtEFG1 catalyzes the translocation of
tRNAs from P to exit (E) site of the mitoribosome, while
mRNA is advanced by one codon. This last step has been
derived from the prokaryotic model; the E site has been
suggested to be very weak or even absent in the mitoribo-
some. Finally, the tRNA leaves the mitoribosome and a new
elongation cycle can start. The functional role of mtEFG2 in
mitochondrial translation is not completely understood.
The termination phase initiates with the recognition of
a stop codon by the mitochondrial release factor (mtRF1
or mtRF1a). This causes the detachment of the polypeptide
linked to the last tRNA present in the P site. After release
of the newly synthesized protein, mitochondrial ribosome
recycling factors (mtRRF and possibly mtEFG2) enable the
mitoribosomal subunits, tRNA and mRNA, to dissociate
from each other, allowing the reuse of them for a new round
of protein synthesis [7, 8].
Mitochondrial disorders with different clinical
presentation have been associated with defects in several
enzymes involved in mitochondrial translation including
tRNA-modifying enzyme like TRMU (tRNA 5-methylami-
nomethyl-2-thiouridylate methyltransferase, OMIM
#613070) [9] and MTO1 (Mitochondrial Translation Opti-
mization 1, OMIM#614702) [10] or elongation factors
like GFM1/EFG1 (OMIM#609060), TSFM/EFTs (OMIM
#610505), and TUFM/EFTu (OMIM#610678) [11, 12].
3. Aminoacyl-tRNA Synthetases
Aminoacyl-tRNA synthetases (aaRSs) are key enzymes in the
translation of the genetic information. In fact, they catalyze
the specific attachment of each of the 20 amino acids (aa) to a
cognate tRNA, through a two-step reaction, where they first
activate the amino acid with ATP, forming an intermediate
aminoacyl-adenylate, and then transfer the aminoacyl group
to the 3󸀠-end of its own tRNA [3, 13].
With the exception of GARS and KARS, mitochondrial
and cytoplasmic aaRSs are encoded by distinct nuclear genes.
The gene for mitochondrial glutaminyl-tRNA synthetase has
not been found yet, possibly becausemitochondrial glutamyl-
tRNA synthetase (EARS2) efficiently misaminoacylates mt
tRNAGln to form glutamate charged-tRNAGln [14]. Hence,
mt-aaRSs are 19 instead of 20, including the 2 with double
localization.
Mt-aaRSs are encoded by nuclear genes (aaRS2),
imported into mitochondria, and their interaction with
cognate tRNAs seems to be essential for their amount
and stability [15]. Mt-tRNA genes are located in three
transcription units: the short H-strand unit (with the rRNA
region and two tRNA genes) is transcribed twice as fast
as the L-strand that contains eight tRNA genes and more
frequently then the entire H-strand unit that produces 14
tRNAs. King and Attardi showed that steady-state levels of
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different tRNAs remain uniform suggesting a mechanism of
posttranscriptional regulation of redundant tRNAs [16].
aaRSs structure typically presents a catalytic domain
and an anticodon binding domain; some of them have also
an editing domain to deacylate mischarged amino acids,
preventing insertion of incorrect amino acids during protein
synthesis [17]. These enzymes can be classified into two
distinct classes according to the structure of the catalytic site:
class I enzymes bear the classical Rossmann fold (defined
as an adenylic-nucleotides recognition site) that displays
five parallel 𝛽-strands connected via 𝛼-helices and the two
signaturemotifs; class II enzymes display an alternate folding,
mainly constituted by a sheet of six antiparallel 𝛽-strands and
three motifs of less-conserved sequences [18].
During evolution, aaRSs have acquired additional
domains and insertions thus expanding their range of
function. Cytosolic aaRSs have been discovered to play
many other roles with either extracellular (cytokines or
angiogenesis regulators) or cytoplasmic activities being
involved in apoptosis, synthesis of rRNA, or tRNA export
to the cytosol. On the other hand, also mt-aaRSs have been
investigated for having additional functions; for instance,
it has been demonstrated that the yeast homologue of
human mitochondrial lysyl-tRNA synthetase is a dual
function protein, involved in both aminoacylation of
mitochondrial tRNALys and import of cytosolic tRNALys into
mitochondria[19].
4. Aminoacyl-tRNA Synthetases and
Mitochondrial Disorders
An increasing fraction of mitochondrial protein synthesis
deficiencies are caused by mutations in one of the aaRS2
genes and have been associated with diverse clinical pre-
sentations, usually with an early onset and transmitted as
autosomal recessive traits. Such a broad clinical spectrum
can be partially explained by the multiple and still unknown
functions of mt-aaRSs. However, there is a strict genotype-
phenotype correlation for most of these genes, albeit the
reason for specific and different cellular or tissue damage,
being all aaRSs ubiquitous enzymes working in the same
pathway is not clear. Because of the fundamental function of
these enzymes, it has been suggested that mt-aaRSs loss of
function mutations is not compatible with extrauterine life
and that a residual enzymatic activity can result in different
tissue alterations after development [20].
We present an overview of the main clinical presen-
tations associated with mutations in aaRS2s, which have
been identified in the last 10 years, initially by linkage
mapping/homozygosity mapping and candidate gene anal-
ysis and, more recently, by next-generation whole exome
sequencing (WES).
4.1. DARS2. DARS2, encoding the mitochondrial aspartyl-
tRNA synthetase (mt-AspRS), was the first aaRS2 gene
reported to cause a human disease, characterized by a pecu-
liar leukoencephalopathy named LBSL (leukoencephalopa-
thy with brain stem and spinal cord involvement, OMIM
#611105) [21] associated with cerebellar ataxia, spasticity, and
variable degree of cognitive impairment. To date, more than
30 families have been described with mutations in DARS2
(Table 1). In mutant patients, high lactate has been observed
only in the affected white matter. White matter changes,
involving brain stem and spinal cord tracts, are very peculiar.
Almost all patients with LBSL are compound heterozygotes,
sharing a complex rearrangement in one allele that involves
a T-C stretch upstream from exon 3 (228-20/-21delTTinsC)
and a second variable, usually missense, mutation.The splice
site mutation in intron 2 is a hypomorphic mutation that
partially interferes with the splicing of exon 3, leading to
frameshift and premature truncation (Arg76SerfsX5) of only
a fraction ofDARS2 transcripts, maintaining somemt-AspRS
residual activity. Van Berge et al. tried to explain the brain
tissue specificity showing differences in mRNA splicing pro-
cess between neurons and other cells [22]. Some compound
heterozygous patients have been reported to show atypical
presentations including specific MRI pattern associated with
no clinical symptoms [23] or no lactate elevation [24]. Axonal
neuropathy was an important and frequent feature of LBSL
[25]. Homozygous DARS2 mutations have been shown to
cause a more severe phenotype [26, 27] or exercise-induced
paroxysmal gait ataxia and areflexia [28].
Surprisingly, blue-native PAGE as well as spectropho-
tometric measurements often revealed normal OXPHOS
enzyme activities in muscle and cultured cells.
4.2. RARS2. Mutations in RARS2 gene have been described
so far in more than 10 families (Table 1). The first patients
described with mutations in RARS2, the gene encoding
for the mitochondrial arginyl-tRNA synthetase (mt-ArgRS),
presented progressive atrophy in cerebellum, pons (ponto-
cerebellar hypoplasia type 6, PCH6; OMIM#611523), with
cerebral cortex and white matter involvement, causing a
severe infantile clinical picture characterized by lethargy,
seizures with apneic spells, hypotonia, and premature death.
These consanguineous Sephardic Jewish patients harboured
a homozygous splice site variant (IVS2 +5A>G) [29] and
showed multiple RC defects in muscle and fibroblasts. How-
ever, at least three RARS2mutant patients, carrying missense
mutations, have been reported without any RC defect in
muscle [30, 31]. Later, it has been demonstrated that the
subtype 1 of pontocerebellar hypoplasia (OMIM#607596),
characterized by a neuropathological profile with loss of
spinal anterior horn cells, diffuse gliosis, flat cerebellar folia,
loss of Purkinje cells, and pontocerebellar hypoplasia, can
be also caused by mutation in RARS2 [32]. Recently, com-
pound heterozygous RARS2 mutations have been described
in patients with neonatal onset epileptic encephalopathy
and typical PCH6 MRI findings. These mutations have
been shown to cause reduced RARS2 amount and activity,
associated with impaired tRNAArg stability [31].
4.3. YARS2. YARS2 encodes for the mitochondrial tyrosyl-
tRNA synthetase (mt-TyrRS). Only two missense mutations
in this gene have been reported till now, associated with
myopathy, lactic acidosis, and sideroblastic anemia (MLASA,
International Journal of Cell Biology 5
OMIM#613561). These mutations, present in homozygous
state in different patients, affect the enzyme catalytic domain
causing generalized mitochondrial translation defect in
myoblasts [33]. Recently, a more severe phenotype has been
described associated with the known homozygous muta-
tion c.156C>G; p.Phe52Leu [34]. Complexes I, III, and IV
were defective in skeletal muscle but not in fibroblasts.
Gel filtration experiments showed that mt-TyrRS is part of
high-molecular-weight complexes (∼250 kDa and 1MDa),
suggesting that, like some of the cytoplasmic aaRSs,mt-aaRSs
could also occur in high-molecular-weight complexes [35].
4.4. SARS2. Belostotsky et al. [36] described three probably
related Palestinian infants with a homozygous mutation
c.1169A>G (p.Asp390Gly) in SARS2, the gene encoding
the mitochondrial seryl-tRNA synthetase (mt-SerRS). They
were affected by a multisystem disorder, characterized by
prematurity, progressive renal failure leading to electrolyte
imbalances, metabolic alkalosis, and pulmonary hyperten-
sion, called HUPRA syndrome (Hyperuricemia, pulmonary
hypertension, renal failure, and alkalosis, OMIM#613845),
and died within the first 14 months of life. Global develop-
mental delay was an additional feature.
Mt-tRNASer catalyzes the ligation of serine to two
mitochondrial tRNA isoacceptors: tRNASer(AGY) and
tRNASer(UCN).TheAsp390Glymutation impacts the acylation
of tRNASer(AGY) but probably not that of tRNASer(UCN) with
severe decrease in the expression of the nonacylated tran-
script and the complete absence of the acylated tRNASer(AGY).
Recently, a novel SARS2 homozygous mutation
c.1205G>A (p.Arg402His) has been identified in a girl
and her brother with HUPRA syndrome [37].
4.5. AARS2. AARS2 encodes themitochondrial alanyl-tRNA
synthetase (mt-AlaRS). All alanyl-tRNA synthetase orthologs
have an aa binding pocket equally accessible by alanine,
serine, and glycine; hence, this enzyme contains an editing
domain, in addition to the catalytic one, essential to deacylate
the mischarged tRNAs. In 2011, Go¨tz et al. [38] described
AARS2mutations causing hypertrophic cardiomyopathy and
lactic acidosis in infants from two different families, one
being homozygous for the p.Arg592Trp mutation and the
other being compoundheterozygous for the p.Arg592Trp and
the missense p.Leu155Arg. All patients died at few months
of age; they showed a drastic deficiency of RC complexes I,
III, and IV in heart tissue, with less severe defects in brain
and skeletal muscle (OMIM#612035). Patients’ fibroblasts or
myoblasts did not show any OXPHOS defect. p.Arg592Trp
localizes in the editing domain, thus probably affecting the
recognition of mischarged tRNAs, while the other missense
mutation is located in the aminoacylation domain.
AARS2 mutations can be also associated with a different
clinical presentation, characterized by cerebellar ataxia and
psychotic features with leukoencephalopathy [39].
4.6. MARS2. Bayat et al. [40] describedmutations inMARS2
encoding the mitochondrial methionyl-tRNA synthetase
(mt-MetRS), which cause autosomal recessive spastic ataxia
with leukoencephalopathy (ARSAL or spastic ataxia 3,
OMIM#611390) in humans and neurodegeneration in flies.
Patients’ brain MRI showed cerebellar atrophy and white
matter alterations sometimes associated with thin corpus
callosum; disease onset was very variable. In all ARSAL
subjects, complex gene rearrangements were identified in
MARS2, including homozygous duplication or compound
heterozygous duplication-deletion (in this last case, disease
onset was anticipated). Despite increased levels of aberrant
MARS2 transcripts, protein levels were lower in all patients.
Furthermore, patients’ fibroblasts displayed a reduced com-
plex I activity as in mutant flies and immortalized lym-
phoblast lines showed an impaired translation [40].
4.7. HARS2. Mutations in HARS2, encoding the mito-
chondrial histidyl-tRNA synthetase (mt-HisRS), have been
associated with Perrault syndrome in a family with five
members affected (OMIM#614926). Perrault syndrome is
a clinical entity characterized by ovarian dysgenesis and
sensorineural hearing loss. This recessive syndrome is genet-
ically heterogeneous, being caused by mutations in different
genes (HSD17B4, CLPP, and LARS2, besides HARS2), and
is associated with premature ovarian failure in females and
progressive hearing loss in both males and females. The
HARS2 mutant patients were compound heterozygous for
two missense mutations, p.Val368Leu and p.Leu200Val, the
latter creating an alternative splice site that causes an in-
frame deletion of 12 codons. Bothmissense mutations caused
significantly decreased enzyme activity compared to wild
type.The enzymatic defect and the oxidative phenotype in the
yeast model were more severe for the p.Val368Leu mutation
[41].
4.8. LARS2. More recently homozygousmutations in LARS2,
encoding the mitochondrial leucyl-tRNA synthetase (mt-
LeuRS), have been found in patients with Perrault syn-
drome (OMIM#615300). Three affected subjects from a
consanguineous Palestinian family carried a homozygous
p.Thr522Asn substitution of a highly conserved residue in
the catalytic domain,whereas compoundheterozygousmuta-
tions were found in a Slovenian woman [42]: a c.1866C>T
transition resulting in a p.Thr629Met substitution at a residue
conserved in mammals, and a 1-bp deletion (c.1077delT)
predicted to yield a 373-amino-acid truncated protein with
14 novel amino acids at the C terminus (p.Ile360PhefsTer15).
Analysis in yeast models suggested reduced activity relative
to wild type for the identified mutations [42].
4.9. FARS2. Mutations in the mitochondrial phenylalanine-
tRNA synthetase, FARS2 (mt-PheRS), have been identified by
WES in two couples of siblings, characterized by fatal epilep-
tic encephalopathy, liver disease, and lactic acidosis. Neu-
ropathological findings together with liver disease filled the
criteria for Alpers-Huttenlocher syndrome (OMIM#614946).
All FARS2 mutant patients died within the first two years
of life. The Saudi siblings were homozygous for a homozy-
gous 431A-G transition, resulting in a Tyr144Cys (Y144C)
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substitution at a highly conserved residue in the catalytic
domain [43]. The Finnish siblings were compound het-
erozygous for two missense variants, c.986T>C (p.Ile329Thr)
and c.1172A>T (p.Asp391Val), affecting residues in the ATP-
binding site in the aminoacylation domain, or in the anti-
codon stem-binding domain, respectively [44]. Blue-native
gel electrophoresis showed a defective complex IV in both
brain and muscle, whereas complex I was decreased only
in brain. Patients’ fibroblast displayed neither biochemical
defects nor impaired mitochondrial translation [44].
Recently, a partial genomic deletion and a p.Asp325Tyr
missense mutation in FARS2 have been described in a patient
with early-onset epilepsy and isolated complex IV deficiency
inmuscle.The biochemical defect was found inmyoblasts but
not in fibroblasts and was associated with decreased steady-
state levels of COXI and COXII proteins and reduced steady-
state levels of the mt-tRNAPhe transcript [45].
4.10. EARS2. EARS2 encodes for the mitochondrial
glutamyl-tRNA synthetase (mtGluRS). Mutations in this
gene have been identified by WES in a single Italian patient
and then found in 11 additional patients with similar MRI
alterations, described as LTBL (leukoencephalopathy with
thalamus and brain stem involvement and high lactate,
OMIM#614924) [46]. Only one additional patient with
EARS2 mutations has been described to date [47]. EARS2
mutant patients presented a peculiar biphasic clinical course:
an infantile disease onset with rapid progression followed by
stabilization, and in some cases improvement, and partial
recovery of lost skills. MRI displayed abnormal thalami,
midbrain, pons, and medulla oblongata and alterations of
cerebral and cerebellar white matter. High blood lactate and
OXPHOS defects in muscle and fibroblasts were present.
All patients were compound heterozygous for a severe
mutation and a milder one, suggesting that there is a
threshold for mtGluRS activity to cause the disease. The
only patient reported with a homozygous severe mutation
(p.Lys65Glu) presented a dramatic phenotype with brain and
liver involvement and a fatal outcome at age 3 months [47].
4.11. VARS2 and TARS2. Recently, mutations in other two
mt-aaRSs have been reported as causative of severe recessive
infantile disorders with OXPHOS deficiency. A homozygous
missense mutation (p.Thr367Ile) in VARS2, the gene encod-
ing themitochondrial valyl-tRNA synthetase (mt-ValRS), has
been found in a child with psychomotor delay, seizures, and
facial dysmorphisms. Two siblings with phenotype character-
ized by hypotonia, psychomotor retardation, and premature
death were found to be compound heterozygous for a splice
site (c.695 +3A>G) and a missense (p.Pro282Leu) mutation
in the mitochondrial threonyl-tRNA synthetase gene TARS2
[39].
4.12. GARS and KARS. In addition to genes coding for
mitochondrial-only or cytosolic-only aaRSs, two genes,
GARS and KARS, encode enzymes, glycyl-tRNA synthetase
(GlyRS) and lysil-tRNA synthetase (LysRS), which catalyze
the reaction in both mitochondria and cytosol.
Dominant GARS mutations have been found in
patients with Charcot-Marie-Tooth disease type 2D
(CMT2D; OMIM#601472) and with distal hereditary
motor neuronopathy type VA (HMN5A; OMIM#600794)
[48, 49]. Experimental evidence demonstrated a key role
for glycine-tRNA synthetase in maintaining peripheral
axons [50]. More recently a toxic role of mutant GARS
on peripheral nerves has been shown [51]. The dominant
transmission can be ascribed to either loss of function
(haploinsufficiency) or a dominant-negative loss-of-function
effect, but also aberrant pathogenic function of the mutant
protein has been hypothesized [52]. Remarkably, most of the
known mutations in cytoplasmic ARSs are associated with a
CMT phenotype or related neuropathies. Mutations in YARS
have been described in patients with Dominant Intermediate
(DI) CMT type C [53], whereas AARS mutations have been
found in patients with a CMT2 phenotype [54] and CMT2N
[55]; HARS mutations have been also associated with axonal
peripheral neuropathy [56].
Mutations in KARS have been initially described in a
patient with an intermediate form of autosomal recessive
Charcot-Marie-Tooth disease (CMTRIB; OMIM#613641)
[57], developmental delay, self-abusive behavior, dysmorphic
features, and vestibular schwannoma. The p.Tyr173SerfsX7
variant represents a loss-of-function allele, and p.Leu133His
represents a severely hypomorphic allele in yeast growth
and aminoacylation assays, respectively. The presence of
compound heterozygosity for a null and severely hypomor-
phic KARS allele may explain the more severe or complex
neuropathy phenotype than those found associated with
other heterozygous dominant-negative aaRS mutation. Very
recently, KARS homozygous missense mutations have been
identified by WES in affected subjects from three consan-
guineous Pakistani families, with nonsyndromic-hearing-
impairment phenotype [58]. No auditory neuropathy and
CMT were reported. It has been hypothesized that KARS
variants affect aminoacylation by interfering with binding
activity to tRNA and with formation of the active LysRS
tetramer. Because of the proven localization of LysRS within
the cochlea, the authors suggested that perturbations in
aminoacylation might affect many of the cellular processes
of the different specialized cells of the cochlea and therefore
result in hearing impairment.
As GARS and KARS encode for both the mitochondrial
and cytoplasmic aaRSs, the evaluation of mitochondrial
involvement in these phenotypes is complicated and has not
been studied in detail.
5. Functional Studies
Given the function of the mt-aaRSs, pathogenic mutations
are expected to impair binding between tRNAs and their
cognate amino acids, resulting in reduction of charged tRNA,
albeit other defects can be envisaged, such as defective mito-
chondrial targeting. However, analysis of amino acylation
is a tricky process that requires a large amount of starting
material, and it is rarely performed. Usually the target of
the studies is a downstream effect of mt-aaRSs dysfunction,
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such as altered mitochondrial protein synthesis or OXPHOS
deficiency.
The lack of clear biochemical phenotypes (OXPHOS or
mitochondrial protein synthesis defects) in skin fibroblasts
andmyoblasts frommost ofmutant aaRS2 patients prevented
the use of cultured cells for functional studies. In few
RARS2 patients, fibroblasts showed OXPHOS defects, with
RC enzymes variably affected;YARS2 patients presented defi-
cient mitochondrial protein synthesis in myotubes but not
in cultured fibroblasts. Microscale oxygraphy (by Seahorse
instrument) could be a more sensible approach to reveal
biochemical defects in cell lines: inEARS2mutant fibroblasts,
microoxygraphic analysis revealed reduction of maximal
respiratory rate and reduced oxygen consumption rate to
extracellular acidification rate ratio, reflecting increased pro-
duction of lactate [46]. Otherwise, induced pluripotent stem
cells derived frompatient cell lines, differentiated into various
cell types, may offer advantages in future studies.
The high degree of conservation of several mt-aaRSs
during evolution makes feasible the use of user-friendly
bacterial and yeast model to evaluate the effects of identified
variants on protein function. In some studies, the recom-
binant mt-aaRSs proteins (i.e., mt-PheRS and mt-AspRS)
were expressed and purified in Escherichia coli, allowing the
comparison of enzyme parameters such as catalytic activity,
ATP binding, and protein stability between mutant and wt
species. In other works, (i.e., RARS2, HARS2, LARS2, and
KARS) mutations were studied on facultative aerobic yeast
Saccharomyces cerevisiae. The yeast orthologous gene can be
inactivated by homologous recombination and the resulting
cells then transformedwith a centromeric plasmid containing
either the wild type or a mutant allele. Usually, all strains are
able to grow in amedium containing a fermentable sugar, but
strains with mutations affecting the OXPHOS system show
decreased or abolished respiration and display a reduced
growth on nonfermentable medium [31]. A restriction in
the use of this approach is the high number of yeast aaRS
genes coding enzymes with a double localization, both mito-
chondrial and cytosolic [59]. This limitation can be bypassed
with a more complex strategy, based on the inactivation of
the endogenous bifunctional enzyme and the reexpression of
modified plasmids coding specifically either the cytosolic or
the mitochondrial enzyme.
At the moment, no mouse model for mt-aaRSs has been
fully characterized and published. Only two mutagenesis-
induced mouse models for GARS have been described: a
dominant model caused by an in-frame indel mutation at
pro278 [52] and a second model with a point mutation
(C201R) that leads to a nonconservative substitution [60].
The first model presented sensorimotor polyneuropathy
with overt neuromuscular dysfunction and shortened life
spans. Heterozygousmutantmice showed neurodegenerative
changes at the neuromuscular junctions, whereas homozy-
gous mutant mice were embryonic lethal. The dominant
transmission was probably due to a gain of function [52].The
second model was less severe but displayed locomotor and
sensory deficits, with myelination defects not detected in the
former model, representing a valuable resource to study the
mechanism of axonopathy resulting from GARS mutations
[60].
The group of Aleksandra Trifunovic is currently dealing
withDARS2mouse models. They recently reported that con-
stitutive Knock-Out (KO) mice had an early developmental
arrest with embryonic lethality, whereas conditional cardiac
and skeletal muscle KOmice showed dramatically shortened
life span and a gradual increase in heart/body weight ratio,
with strong reduction of all assembled respiratory chain
complexes, except complex II, in both heart and skeletal mus-
cle [61]. Two probably more interesting mouse models are
undergoing study, based on different brain-specific DARS2
depletion in either adult forebrain neurons or in myelin-
producing oligodendrocytes.
The production of conditional tissue-specific mouse
models for different mt-aaRSs could provide an insight into
the pathological mechanisms and the selective tissue involve-
ment caused by mutations in these ubiquitously expressed
enzymes.
6. Discussion
It is hard to explain why genetic defects in mt-aaRSs,
which are ubiquitous enzymes necessary for mitochondrial
translation, can cause so many different phenotypes usually
affecting specific tissues or organs. Different hypotheses have
been proposed to explain this variability, but none seems to
cover all aspects of this phenomenon, that is probably the
result of several different mechanisms altered in mt-aaRSs
mutant patients.
The first patients with splice-site mutation in either
DARS2 or RARS2 presented with encephalopathy. Differ-
ences in mRNA splicing machinery, in abundance of splicing
factors, and splicing efficiency between neuronal and other
cell types have been hypothesized to explain this tissue speci-
ficity. However, other patients harbouring DARS2 or RARS2
missense mutations have been reported later weakening the
general value of this hypothesis. In addition to DARS2 and
RARS2mutations, also the tissue specificity present inHARS2
mutant patients may be influenced by splicing efficiency in
different tissues/organs, in the latter case ovaries and ears.
However, only one family has been described till now and
the identification of other patients with HARS2 mutations is
required to confirm this observation.
Other types of mutations and their location inside the
protein could have an influence on the resulting phenotype.
For instance, the AARS2 p.Arg592Trp mutation is located
at the surface of the editing domain, which functions in
deacylating the mischarged tRNAs, and is predicted to affect
the recognition of mischarged tRNAs [38]. The pathogenic
mechanism of this mutation may be linked to mitochondrial
mistranslation and hence be different from other mt-aaRS
defects. Why mistranslation would lead specifically to car-
diomyopathy, while translation deficiencies caused by other
mt-aaRSs mutations are usually not associated with heart
damage remains an open question. Noteworthy, mutations
affecting MTO1, an enzyme responsible for tRNA modifica-
tions that increases the accuracy and efficiency of mtDNA
8 International Journal of Cell Biology
translation, have been found in patients with hypertrophic
cardiomyopathy [62].
Alternatively, the bigger susceptibility of some cell types,
in particular neurons, for aminoacyl-tRNA synthetase dys-
function could be linked to the variable expression of mito-
chondrial tRNAs in different cells, to the amount of cognate
amino acid in a particular tissue [38], or to different threshold
required for optimal enzymatic activity of each mt-aaRS.
The brain expresses higher levels of mitochondrial-encoded
tRNAs as compared to other examined tissue, including liver,
vulva, testis and ovary, thymus, lymph node, and spleen
[63]. Moreover, variations in the relative expression of tRNA
isoacceptors among tissues have been observed: thus the
tRNA levels could influence the usage of different codons
among different tissues [63].
For AARS2 mutations, the tissue-specific manifestation
of the cardiomyopathy could be explained by variable amino
acid concentrations in different tissues; in fact, increased
levels of alanine have been found in affected tissue (heart
and muscle), but not in the unaffected liver. This observation
could be due to a compensatory feedback mechanism occur-
ring upon deficient tRNAAla aminoacylation or be an unspe-
cific response to RC defect reflecting the alanine secreted
from RC-deficient skeletal muscle for gluconeogenesis [38].
For some peculiar phenotypes, the pathological mech-
anisms seem to be specific and unique. In addition to
YARS2 mutations, MLASA can be caused also by mutation
in PUS1, encoding pseudouridylate synthase 1. This enzyme
is probably responsible for pseudouridylation of tRNATyr.
This observation suggests that tRNATyr and not a general
mitochondrial translation defect is specifically responsible
for the combined myopathy and anemia in YARS2 mutant
patients.
GARS and KARS, encoding enzymes acting both in
mitochondria and cytosol, require ad hoc comments and
considerations. Few pathological pictures, mainly CMT, have
been described caused by defective cytoplasmic aaRSs; hence,
the neuropathy phenotypes associated with GARS or KARS
mutations have been ascribed mainly to impairment of the
cytoplasmic enzyme. However, the possible contribution of
faulty mitochondrial functionality in the development of the
phenotype has not been fully analyzed. It should be noted
that axonal CMT is frequently caused by mutations in a
mitochondrial protein, MFN2, involved in mitochondrial
fusion; however, it is not known if and how GlyRS or LysRS
could be linked directly to mitochondrial dynamics or how
a mitochondrial synthesis deficiency could lead to axonal
dysfunction.
While mutations in GARS or other cytosolic aaRSs are
inherited as dominant trait,KARSmutation are recessive and
the presence of two mutant alleles has been suggested as
responsible for the most severe phenotype in these patients,
including acoustic neuroma and dysmorphisms besides CMT
[57]. More recently, recessive KARS mutations have been
reported in patients with nonsyndromic hearing impairment
without neuropathy, expanding the spectrum of phenotypes
associated with KARS mutation [58]. Unfortunately, the
selective impairment of mitochondrial protein synthesis has
not been investigated in these patients. Interestingly, hearing
problems are present also in patients with PCH6 (due to
RARS2 mutations) or Perrault syndrome (caused by LARS2
or HARS2 mutations). In addition, a number of different
mutations in several genes of the mitochondrial genome,
mainly MTRNR1 encoding the mitochondrial ribosomal
RNA 12S, and many tRNA-encoding genes, are responsible
for hearing impairment or deafness, in some cases associated
with a variety of additional clinical features.
Mutations in DARS, encoding the cytosolic AspRS, have
been recently found in a cohort of patients with a leukoen-
cephalopathy characterized by hypomyelination with brain
stem and spinal cord involvement and legs spasticity (HBSL,
OMIM#615281) [64]. HBSL resembles LBSL, which is caused
by mutations in DARS2, suggesting that these two diseases
might share a common underlying molecular pathology.
Many aaRSs have additional functions beyond translation
[19, 65] including AspRS, which is involved in asparagine
biosynthesis [66]. It is possible that a common function for
DARS and DARS2, not strictly related to aminoacylation,
could be responsible for the very similar clinical presentations
in HBSL and LBSL.
Increasing evidences suggest that mt-aaRSs have a role
as “chaperone,” besides their enzymatic function. According
to the “channeling” hypothesis [15], interaction of mitochon-
drial tRNA with proteins, including mt-aaRSs, are not only
necessary for tRNA synthesis, maturation, and function but
also to protect tRNAs from degradation. Rapid turnover of
free mt-tRNAs, not aminoacylated or bound to any protein
partner, provides a general mechanism for the quality control
of the tRNA pool within the human mitochondria. The data
obtained from studies on mutated mt-tRNA support this
hypothesis: pathogenic mutations in mt-tRNA are usually
associatedwith a reduction in tRNAamount and a decrease of
the aminoacylated form [15]. Similar indications came from
studies on patients with aaRS2 mutations. In mutant RARS2
fibroblasts, the amount of tRNAArg transcript is low, but it is
almost fully acylated. A residual ArgRS activity is probably
present that could aminoacylate a small portion of the
tRNAsArg, whereas the uncharged tRNAs become unstable
and are degraded [31]. In lymphocytes from patients bearing
a homozygous SARS2mutation, the amount of tRNASer(AGY)
was strongly reduced and fully nonacylated, whereas the
amount of tRNASer(UCN) isoacceptor was nearly normal.
The authors concluded that mutation in SARS2 significantly
impairs the ability of the enzyme to aminoacylate selectively
the tRNASer(AGY), leading to degradation of the uncharged
tRNA molecules [36]. Therefore, mutations affecting either
mt-tRNAs or mt-aaRSs, perturbing their “stabilizing” inter-
action, lead to decreased tRNA levels.
Additional findings in support to the channeling theory
have been obtained in both yeast and human cell lines
[15, 67, 68]: the overexpression of cognate, or even noncog-
nate [69], mt-aaRSs has been demonstrated to be able to
reduce/correct the deleterious effects of somemt-tRNA point
mutations, leading to partial recovery of the steady-state
levels of mutated tRNAs. Notably, the enzymatic activity of
mt-aaRSs seems to be not required for its rescuing effect. In
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yeast carrying tRNA mutations, the recovery has also been
obtained by overexpression of an isolated C-terminal portion
of yeast LeuRS, lacking the catalytic domain [70]; it has been
proposed that this polypeptide may act as a chaperone, by
directly interactingwithmutantmt-tRNAs,making them less
prone to degradation or maintaining them in a structural
conformation fostered to react with the endogenous mt-
LeuRS.
7. Conclusions
Increasing evidences suggest that the pathophysiology of mt-
aaRSs-associated disorders is driven by processes and inter-
actions that are not yet fully understood. For instance, tissue-
specific proteins that could interact differentially with the
wild-type or mutant mt-aaRSs, by inhibiting the enzymatic
activity or any additional function, might be identified.
In general, mt-aaRSs are relatively poorly characterized
enzymes but with growing importance in human mitochon-
drial medicine. Generation of animal models will allow us
to better understand mt-aaRSs functions, interactions, and
possibly tissue specificity. These studies will surely provide
important knowledge about the pathogenetic role of syn-
thetases in the different human diseases.
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